Lipids & metabolic liver disease
Risk stratification of MASLD-related advanced fibrosis using a novel point-of-care device: the Hepatoscope
Authors' conclusion
This proof-of-concept study provides evidence supporting the role of LSM-2DTE using the Hepatoscope in the risk stratification of AF in diabetology settings.
Study context
- Population
- Participants with T2D and/or obesity and MASLD, aged 40–80 years, BMI <40 kg/m²; 83.3% T2D, 42.5% female, 71.4% obesitysubgroup n = 120
- Participants
- 294 participants
- Comparison
- LSM-2DTE vs ELF for detecting LSM-VCTE ≥ 8 kPa
- LSM-2DTE-2n = 120
- Outcome
- AUROC for detection of intermediate to high-risk of advanced fibrosis, defined by LSM-VCTE ≥ 8 kPa
Methodological detailsprospective, multi-centre, proof-of-concept
- Prospective
- Multi-centre
- Proof-of-concept
Performance
As reported in the abstract
AUROC for detection of LSM-VCTE ≥ 8 kPa
| Test or model | Area under the ROC curve (AUROC) |
|---|---|
| LSM-2DTE-2 | 0.81 (95%CI 0.72-0.89) |
| ELF | 0.64 (95%CI 0.52-0.75) |
Area under the ROC curve (AUROC)
LSM-2DTE-20.81 (95%CI 0.72-0.89)
ELF0.64 (95%CI 0.52-0.75)
Further findings
| Outcome | LSM-2DTE-2 | LSM-2DTE-1 |
|---|---|---|
| Correlation with LSM-VCTE | ||
| R | 0.61 [0.47-0.71], P < 0.001 | 0.37 [0.26-0.47], P < 0.001 |
Prevalence of LSM-VCTE ≥ 8 kPa
- Participants with LSM-VCTE ≥ 8 kPa
- 24.8%
Original publication
Risk stratification of MASLD-related advanced fibrosis using a novel point-of-care device: the Hepatoscope. Diabetes Metab. Published 8 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →